Influence of fenofibrate on blood rheology in type II hyperlipoproteinemia¹

Article type: Research Article

Authors: Arntz, H.-R. | Gogolwske, I. | Heitz, J. | Schäfer, J.-H. | Schröder, R.

Affiliations: Medical Clinic, Department of Cardiology and Pulmonology, Steglitz Medical Center, Free University of Berlin, Hindenburgdamm 30, D-1000 Berlin 45, FRG

Note: [1] Supported in part by Deutsche Forschungsgemeinschaft (Ga 225/6–1) and Laboratoires Fournier, Dijon, France.

Note: [] Accepted by: Editor A.M. Ehrly

Abstract: In a randomized double-blinded placebo-controlled study the effects of 100 mg fenofibrate TD were investigated in 22 patients suffering from hyperlipoproteinemia type IIa and IIb with respect to whole-blood viscosity, erythrocyte aggregation, plasma viscosity, fibrinogen, and lipoprotein concentrations. Fenofibrate led to significant decreases of VLDL and LDL lipoprotein concentrations. Fibrinogen and alpha 2 macroglobulin remained constant. Whereas whole-blood and plasma viscosity was reduced significantly, erythrocyte aggregation remained unchanged under fenofibrate. We conclude that the reduction of blood viscosity is due to the change in lipoprotein concentrations, mainly LDL fraction, even if we found no quantitative correlation between the parameters.

Keywords: Hyperlipoproteinemia, Rheology, Aggregation, Fenofibrate, Fibrinogen

DOI: 10.3233/CH-1990-10304

Journal: Clinical Hemorheology and Microcirculation, vol. 10, no. 3, pp. 297-307, 1990